CTLA4 and neoplasm: As shown in figure 3, as starting tumour size increases, the tumours progressively grow with anti-CTLA-4 monotherapy, while in response to anti-PD-L1 monotherapy and combination therapy tumours with initial size of 35 mm and smaller regress, whereas tumours with initial size above 40 mm grow.